Navigation Links
Suven Life Sciences Presenting Pre-clinical data of their,NCE’s SUVN-502 and SUVN-507at International Brain Research,Organization (IBRO) 2007 World Congress of Neuroscience

HYDERABAD, India, July 5th, 2007 – Several data presentations from Suven’s portfolio of investigational neuroscience compounds will be presented at International Brain Research Organisation (IBRO) 2007 World Congress of Neuroscience to be held at Melbourne, Australia during July 12-17, 2007.

Scientists from Suven Discovery Research will be presenting new data for 4 promising areas of neuroscience viz. Alzheimer’s, Schizophrenia, Parkinson and Obesity diseases. These areas present significant unmet medical need for which current treatment options are insufficient. Suven has a number of programs in each of these areas, focusing on novel approaches that may lead to the development of new therapies for patients.
Suven is presenting the data on their leading preclinical candidates SUVN-502 and SUVN-507 at IBRO 2007 world congress of Neuroscience .

Suven is committed to neuroscience research and for development of new treatments for neurological disorders. Suven’s discovery research focuses on Central Nervous System (CNS) disorders through novel mechanisms using small-molecule medicinal chemistry approaches. Suven’s CNS drug discovery scientists at Hyderabad, India are pursuing innovative ways to develop treatments for a variety of CNS disorders like Alzheimer's, Schizophrenia, Depression, Cognitive disorders and Neurodegeneration.

Suven Life Sciences, a Hyderabad based Life Sciences Company, pioneer in Contract Research And Manufacturing Services (CRAMS) since 1995 in its endeavor to become collaborative research partner (CRP) for global life science companies has embarked on new business model “Drug Discovery and Development Support Services” (DDDSS) with the onset of Intellectual Property Regime in India since January 2005.

A focused provider of DDDSS for development of New Chemical Entities to life sciences companies, Suven ’s commitment to protection of intellectual property, maximization of return on R&D investments for collaborative research partners, ability to offer full spectrum of services from discovery to market launch and provide technologies and expertise in different therapeutic areas. Suven has R&D strength of more than 190 professionals with the state of the art infrastructure for Drug Discovery and development activities with 30 clinical research professionals and the front-end project management services from New Jersey, USA. For more information on Suven, please visit our Web site at http://www.suven.com

Risk Statement:
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive.


Serene Chambers, Road No.5, Avenue 7, Banjara Hills Hyderabad 500034, India

Tel: 91-40-2354 1142 Fax: 91-40-2354 1152 Email: info@suven.com


'"/>




Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
4. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. Answerthink and LORENZ Life Sciences Group Announce Strategic Alliance for the SAP Life Science Industry
7. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
8. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
9. Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
10. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
11. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... 2017 Diabetic Shoes Market: Overview Read ... ... a disease, which is marked by high levels of blood ... The disease has become a global epidemic leading to serious ... organs of the body including eyes, kidneys, heart. However, it ...
(Date:2/21/2017)... 21, 2017 Medical Oxygen Concentrators Market: ... http://www.reportlinker.com/p04711311-summary/view-report.html Medical oxygen concentrators are used ... diseases. Patients having low level of oxygen in ... Oxygen concentrators are to be used only with ... Medical oxygen concentrators work either on rechargeable lithium ...
(Date:2/21/2017)... Feb. 21, 2017  Global health services company Cigna ... ® for breast reconstruction surgery and Dermacell ... an advanced acellular dermal matrix developed by LifeNet Health ... NVDQ ) "We are proud ... health-care payers to review the growing base of evidentiary ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... February 21, 2017 , ... Hanna Boys Center http://www.hannacenter.org ... be the keynote speaker at its second Professional Networking Breakfast on March 9, ... develops comprehensive strategies to create and expand opportunities for boys and young men ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... conditions and problems directly related to surgery, treatment, therapy and management. Regular exercise ... enjoy better qualities of life despite their diseases. On February 23, 2017, 1:00-2:00 ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... coverage in veterinary medicine, will be launching its first bi-monthly issue of 2017 ... medicine, business and practice management, and One Health. , In making the ...
(Date:2/21/2017)... , ... February 21, 2017 , ... ... acquisition of the predictive analytic firm Predixion’s Healthcare IT practice. Predixion, which raised ... and is backed by giants including Accenture, GE Ventures, and Software AG ...
(Date:2/21/2017)... ... February 21, 2017 , ... A February 6 article ... for weight loss. It found that the treatments have led to significant improvements in ... compared to unassisted efforts. It also noted very few problematic results relating to the ...
Breaking Medicine News(10 mins):